Regulatory pathway · all topics

NIH SBIR Phase II

NIH SBIR Phase II provides up to $2 million over 2 years (FY2024 amount) for full R&D leading to commercialization. Requires successful Phase I award showing technical merit and feasibility. Direct-to-Phase-II is available for selected topics where Phase I work has been completed under other funding. Applications scored on significance, investigator, innovation, approach, environment. Most NIH institutes accept SBIR; the National Cancer Institute (NCI) and NHLBI run the largest device-relevant programs. Award rates around 16-22% in FY2024.

Source

NIH, 'SBIR/STTR Phase I and Phase II Funding Opportunities'

https://sbir.nih.gov/

How MedTek OS handles this

Compass drafts the nih sbir phase ii workflow with confidence-gated content.

The platform refuses to generate content below the threshold for this artifact class. Every claim carries a citation chain back to RIG, audit-logged with HMAC integrity.

Try the sandbox Ask the agent about this

Related pathways

510(k) Premarket Notification

A 510(k) clearance under 21 CFR Part 807 Subpart E demonstrates substantial equivalence to a legally marketed predicate device. Required for...

De Novo Classification Request

De Novo creates a new classification for a novel low-to-moderate risk device with no valid predicate. Submission under 21 CFR Part 860 Subpa...

Premarket Approval (PMA)

PMA is the most stringent FDA pathway, required for Class III devices that support or sustain human life or pose significant risk. Filed und...

Investigational Device Exemption (IDE)

An IDE under 21 CFR Part 812 allows an unapproved device to be used in a clinical study to gather safety and effectiveness data. Required wh...